Our study also showed the LRRFS and DFS were similar between HFRT and CFRT groups in locally advanced patients with HR+/HER2− and HER2+ BC, suggesting no survival benefits from CFRT under the current care of concurrent endocrine and target therapy (23, 24). This evidence concerns the gene HR and breast cancer.